Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study

BACKGROUND: The pharmacokinetic and clinical behaviors of many proton pump inhibitors (PPIs) in peptic ulcer treatment are altered by CYP2C19 genetic polymorphisms. This non-inferiority study evaluated the efficacy and safety of the novel PPI anaprazole compared with rabeprazole. We also explored th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Huiyun, Pan, Xue, Zhang, Li, Sun, Hongxin, Fan, Huizhen, Pan, Zhongwei, Huang, Caibin, Shi, Zhenwang, Ding, Jin, Wang, Qi, Du, Yiqi, Lyu, Nonghua, Li, Zhaoshen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106214/
https://www.ncbi.nlm.nih.gov/pubmed/36580650
http://dx.doi.org/10.1097/CM9.0000000000002508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106214/
https://www.ncbi.nlm.nih.gov/pubmed/36580650
http://dx.doi.org/10.1097/CM9.0000000000002508

Ejemplares similares